期刊
EUROPEAN JOURNAL OF CANCER
卷 106, 期 -, 页码 144-159出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2018.11.002
关键词
NSCLC; Immunotherapy; Predictive biomarkers; Lung cancer; PD-L1; Tumour mutational burden; Tumour microenvironment; Microsatellite instability
类别
Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed. (C) 2018 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据